EUVIMEDEUVIMED entdecken
Studienprotokoll

Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2 ‐related schwannomatosis

Dorothy Halliday iD, Beatrice Emmanouil iD, D Gareth R Evans iD

Clinical Genetics · 2023

DOI: 10.1111/cge.14310 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Clinical Genetics, 2023. Verfasst von Dorothy Halliday und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Trust, Oxford, UK. Hauptthemen laut MEDLINE: Neurofibromatoses, Neurilemmoma, Skin Neoplasms, Neurofibromatosis 2. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetic testing and management of individuals at risk for NF2 ‐related schwannomatosis is complicated by the high rate of mosaicism resulting in a milder, later onset, more asymmetrical disease and the phenotypic overlap with the related schwannomatosis conditions. This updated protocol has been devised for the English NF2 ‐related schwannomatosis service. It provides those affected with mosaic NF2 ‐related schwannomatosis estimated risks of having an affected child; and management guidelines both for individuals at risk of NF2 ‐related schwannomatosis, or with potential disease, due to having features that fall short of consensus diagnostic criteria. Risks of mosaicism and inferred transmission risks were derived from genetic testing of over 1000 individuals through the Manchester NF2 genetic testing service. This updated protocol, reflects the lower transmission risks now inferred in mosaic NF2 ‐related schwannomatosis, informed by the greater sensitivity of Next Generation Sequencing in detecting low levels of mosaicism in blood, along with improved ability to analyse tumour DNA. Screening for features of NF2 ‐related schwannomatosis is proposed until the risk of having the condition falls below a pragmatic threshold of 1%. Using these revised transmission figures, this threshold can now be reached at a younger age in many of those at risk, with earlier reassurance and discharge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurofibromatosesNeurilemmomaSkin NeoplasmsNeurofibromatosis 2ChildHumansGenetic Testing

Stichwörter der Autor:innen

NF2-related schwannomatosismosaicscreening protocoltransmission risk

Autor:innen und Institutionen

  • Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Trust, Oxford, UK.
  • Oxford NF2 Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Centre for Immunobiology, Blizard Institute, Queen Mary University of London, London, UK.
  • Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.

ORCID-Profile: Dorothy Halliday, Beatrice Emmanouil, D Gareth R Evans

Förderung

  • Department of Health

Zitieren

APA

Halliday, D., Emmanouil, B., & Evans, D. G. R. (2023). Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2 ‐related schwannomatosis. Clinical Genetics. https://doi.org/10.1111/cge.14310

Vancouver

Halliday D, Emmanouil B, Evans DGR. Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2 ‐related schwannomatosis. Clinical Genetics. 2023. doi:10.1111/cge.14310

BibTeX
@article{Halliday2023,
  author = {Halliday, Dorothy and Emmanouil, Beatrice and Evans, D Gareth R},
  title = {Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2 ‐related schwannomatosis},
  journal = {Clinical Genetics},
  year = {2023},
  doi = {10.1111/cge.14310}
}
Kostenlos starten →